These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28954632)

  • 1. Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
    Deluche E; Venat-Bouvet L; Leobon S; Fermeaux V; Mollard J; Saidi N; Jammet I; Aubard Y; Tubiana-Mathieu N
    BMC Cancer; 2017 Sep; 17(1):662. PubMed ID: 28954632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
    Völker HU; Weigel M; Strehl A; Frey L
    Diagn Pathol; 2018 Aug; 13(1):67. PubMed ID: 30170623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
    Vénat-Bouvet L; Fermeaux V; Leobon S; Saidi N; Monteil J; Mollard J; Aubard Y; Jammet I; Tubiana-Mathieu N
    Anticancer Res; 2014 Mar; 34(3):1213-7. PubMed ID: 24596362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
    Pusina S
    Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
    BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Foekens JA; Beex LV; Sweep CG
    Cancer Res; 2004 Jan; 64(2):659-64. PubMed ID: 14744782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
    Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
    Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
    Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Jänicke F; Schmitt M; Pache L; Ulm K; Harbeck N; Höfler H; Graeff H
    Breast Cancer Res Treat; 1993; 24(3):195-208. PubMed ID: 8435475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.
    Witzel ID; Milde-Langosch K; Wirtz RM; Roth C; Ihnen M; Mahner S; Zu Eulenburg C; Jänicke F; Müller V
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1709-18. PubMed ID: 20204407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
    Sereff SB; Daniels MW; Wittliff JL
    J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.